ʻSensitizingʼ Test Paradigms: Demographics and Drugs.

§ not interfering with the MOR-antagonist assessments (drugs without administration route stated are i.v.). # 1mg: cold water challenge; 2mg: ischemic pain challenge. A study includes fibromyalgia patients (n = 15, data not reported here). B study includes fibromyalgia patients (n = 10, data not reported here). C study included patients with chronic low back pain (n = 37; data not reported here) and 2 healthy subjects on antidepressant medication. D study includes chronic low back pain patients (n = 45, data not reported here). E study includes treatment arms of combinations of tilidine (100 mg) and naloxone (8–32 mg; data not reported here). F study includes treatment arms with codeine (60 mg p.o.) and codeine/naloxone (2 mg i.v.; data not reported here). G study includes subjects with borderline hypertension (n = 21, data not reported here). H study includes treatment arm with codeine (60 mg p.o.; data not reported here). I study includes patients with bulimia nervosa (n = 10) and anorexia nervosa (n = 10; data not reported here). J study includes patients with major depression (n = 20; data not reported here). K study includes placebo-controlled treatment arm with ketamine (0.4 mg/kg; data not reported here). L the total number of subjects were 20 (4 were excluded). M the total number of subjects were 12 (2 were excluded). N study includes treatment arms with paracetamol (1g i.v.) and paracetamol/naloxone (8 mg i.v.; data not reported here). SD standard deviation. For explanation of abbreviations, please, refer to legend Table 3. ʻSensitizingʼ Test Paradigms: Demographics and Drugs.